Bio­Marin gets its shot at an­oth­er block­buster as FDA OKs rare dis­ease drug peg­valiase

Bio­Marin $BM­RN has picked up their lat­est OK for their rare dis­ease drug port­fo­lio, with the FDA com­ing through with an ap­proval on peg­valiase, which com­pa­ny ex­ecs have pegged as a block­buster in the mak­ing.

In a call with an­a­lysts Thurs­day evening, Bio­Marin ex­ecs not­ed that they will price the drug at $488 whole­sale a unit, with pa­tients need­ing 1 to 2 units a day. The math sets the av­er­age price for 1.5 units at $267,180 as year, with prices rang­ing up to $356,240, un­der­scor­ing their com­mit­ment to earn­ing more than $1 bil­lion a year from the ther­a­py. The av­er­age net in­clud­ing manda­to­ry gov­ern­ment pric­ing, say com­pa­ny reps, should re­duce that av­er­age to about $192,000.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER